Vosilasarm (RAD140) is a potent, orally active, nonsteroidal selective androgen receptor modulator (SARM) with a Ki of 7 nM. Vosilasarm shows good selectivity over other steroid hormone nuclear receptors.
Vosilasarm (RAD140) is a potent, orally active, nonsteroidal selective androgen receptor modulator (SARM) with a Ki of 7 nM. Vosilasarm shows good selectivity over other steroid hormone nuclear receptors.
Vosoritide (BMN111) is a C-type natriuretic peptide (CNP) analogue that is an endochondral ossification stimulant that binds to specific receptors to initiate intracellular signaling that inhibits the overactive FGFR3 pathway.
Vosoritide (BMN111) is a C-type natriuretic peptide (CNP) analogue that is an endochondral ossification stimulant that binds to specific receptors to initiate intracellular signaling that inhibits the overactive FGFR3 pathway.
Vosoritide (BMN111) is a C-type natriuretic peptide (CNP) analogue that is an endochondral ossification stimulant that binds to specific receptors to initiate intracellular signaling that inhibits the overactive FGFR3 pathway.
Vosoritide (BMN111) is a C-type natriuretic peptide (CNP) analogue that is an endochondral ossification stimulant that binds to specific receptors to initiate intracellular signaling that inhibits the overactive FGFR3 pathway.
Voxelotor (GBT 440) is a first-in-class, potent polymeric inhibitor of sickle hemoglobin (HbS). Voxelotor (GBT440) binds to the N-terminal a chain of haemoglobin (Hb), increases haemoglobin S (HbS) affinity for oxygen, delays in vitro HbS polymerization and prevents sickling of red blood cells (RBCs).
Voxelotor (GBT 440) is a first-in-class, potent polymeric inhibitor of sickle hemoglobin (HbS). Voxelotor (GBT440) binds to the N-terminal a chain of haemoglobin (Hb), increases haemoglobin S (HbS) affinity for oxygen, delays in vitro HbS polymerization and prevents sickling of red blood cells (RBCs).
Voxelotor (GBT 440) is a first-in-class, potent polymeric inhibitor of sickle hemoglobin (HbS). Voxelotor (GBT440) binds to the N-terminal a chain of haemoglobin (Hb), increases haemoglobin S (HbS) affinity for oxygen, delays in vitro HbS polymerization and prevents sickling of red blood cells (RBCs).
Voxelotor (GBT 440) is a first-in-class, potent polymeric inhibitor of sickle hemoglobin (HbS). Voxelotor (GBT440) binds to the N-terminal a chain of haemoglobin (Hb), increases haemoglobin S (HbS) affinity for oxygen, delays in vitro HbS polymerization and prevents sickling of red blood cells (RBCs).
Voxelotor (GBT 440) is a first-in-class, potent polymeric inhibitor of sickle hemoglobin (HbS). Voxelotor (GBT440) binds to the N-terminal a chain of haemoglobin (Hb), increases haemoglobin S (HbS) affinity for oxygen, delays in vitro HbS polymerization and prevents sickling of red blood cells (RBCs).
Voxtalisib (SAR245409, XL765) is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.